Add BrightSurf on Google Email

Impact Journals LLC


Predicting the molecular functions of regulatory genetic variants associated with cancer

Researchers discuss a new approach integrating genomic, epigenomic, transcriptomic, and machine learning methods to identify functional genetic variants and characterize their mode of action in regulating target genes. This method aims to improve understanding of disease etiology and prioritize causative inherited genetic variants.

SourceImpact Journals LLC·JournalOncotarget·TypeData/statistical analysis·DateNov 20, 2023

A potential early esophageal cancer antigen: DDX53

Researchers found that tumor-resident T-cell receptor sequences showed high complementarity with the cancer testis antigen DDX53, suggesting an immune response that selects for DDX53-negative cells. This association was correlated with worse disease-free survival rates, highlighting a potential early esophageal cancer antigen.

SourceImpact Journals LLC·JournalOncoscience·TypeObservational study·DateNov 17, 2023

Parkinson disease and normal aging

Researchers investigate centro-cingulate network changes and cholinergic innervation deficits in Parkinson disease and normal aging. Studies reveal significant correlations between centro-cingulate changes and cognitive impairments, motor symptoms, and age.

SourceImpact Journals LLC·JournalAging-US·TypeCommentary/editorial·DateNov 1, 2023

Suppression of cancer stemness and drug resistance via BRAF/EGFR/MEK inhibition in colorectal cancer cells

Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateOct 11, 2023

B cell response after influenza vaccine in young and older adults

Researchers found a quantitative difference in B cell response following vaccination between young and older adults, with younger adults mounting a stronger clonal response and older adults having more activated B cells. This study provides insights into the age-related differences in B cell vaccine response and may lead to the develop...

SourceImpact Journals LLC·JournalAging-US·TypeObservational study·DateOct 10, 2023

STAT3 as a target in H3K27M-mutant DMGs

Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateOct 10, 2023

Lurbinectedin for Neuroendocrine Tumors (NETs)

Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.

SourceImpact Journals LLC·JournalOncoscience·TypeCommentary/editorial·DateOct 6, 2023

An ancient anti-cancer mechanism: DISE

Researchers at Northwestern University identified a new evolutionarily conserved RNAi-based form of cell death called Death Induced by Survival gene Elimination (DISE), which targets essential survival genes in cancer cells. This mechanism is ancient and effective against all cancers tested.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateOct 3, 2023

Reassessing COVID-19 precautions in 2023

The article discusses the need to reassess COVID-19 precautions in 2023, particularly for patients with hematologic malignancies. The researchers highlight the increased risk of poor response to vaccination and worse outcomes from COVID-19 infection among these patients.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateSep 27, 2023

Kinase-targeted therapy in subsets of colorectal cancer

Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.

SourceImpact Journals LLC·JournalOncoscience·TypeCommentary/editorial·DateSep 22, 2023